Sorrento
Sorrento Therapeutics focuses on the research and development of therapeutic products for the treatment of cancer, inflammation and autoimmune diseases.
Business Model:
Revenue: $60.3M
Employees: 501-1,000
Industries / Tags:
Detailed Sorrento Information
Geographic Data
Address: 4955 Directors Place
City: San Diego
State: CA
Zip: 92121
Country: US
Financial Info
Stage:
post ipo equity
Raised Last:
$25M
Raised Total:$264M
Social
Metrics
1,183,017Website Global Rank
25,941Website Monthly Traffic
Twitter Followers
Description
Sorrento Therapeutics focuses on the research and development of therapeutic products for the treatment of cancer, inflammation and autoimmune diseases.
Contact Phone:
+18582034100
Contact Email:
Sorrento went public on 1/11/2010 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
1/11/2010
Ticker Symbol:
SRNE
IPO Price:
$7.25/share
Amount Raised:
$30M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 1/2015 | NantiBodyFc | Private Equity Round | 0 |
| 7/2021 | Celularity | Post-IPO Equity | 80M |
| 1/2015 | Globavir | Seed Round | 4M |
| 1/2015 | Globavir | Venture Round | 0 |
| 2/2018 | Celularity | Series A | 250M |
| 8/2021 | Aardvark Therapeutics | Series B | 0 |
| 8/2021 | Aardvark Therapeutics | Series B | 0 |
| 7/2021 | Celularity | Post-IPO Equity | 0 |
| 2/2018 | Celularity | Venture Round | 0 |
| 1/2015 | Globavir | Venture Round | 0 |
| 1/2015 | NantiBodyFc | Private Equity Round | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2018 | Post-IPO Debt | $150M |
OakTree Capital Management |
4/2017 | Post-IPO Equity | $43.5M | 4/2020 | Debt | $2M |
U.S. Small Business Administration. |
3/2018 | Private Placement | $120.5M | 10/2019 | Post-IPO Equity | $25M | 6/2009 | Venture Round | $2.3M | 1/2012 | Post-IPO Equity | $2M | 4/2016 | Post-IPO Equity | 1 | $150M |
Ally Bridge Group Ally Bridge Group Ally Bridge Group Ally Bridge Group |
10/2013 | Post-IPO Debt | $1.9M | 3/2013 | Post-IPO Equity | $6.4M | 10/2013 | Debt Financing | $1.9M | 11/2016 | Post-IPO Debt | $75M |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 7/2022 | Ancora Medical Technology | |
| 4/2021 | ACEA Therapeutics | |
| 7/2020 | SmartPharm Therapeutics | |
| 8/2016 | Semnur Pharmaceuticals | |
| 8/2016 | Scilex Pharmaceuticals |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
